סרוקואל 200 מג xr
astrazeneca (israel) ltd - quetiapine fumarate - טבליות עם שחרור נרחב - quetiapine fumarate 200 mg - quetiapine
סרוקואל 300 מג xr
astrazeneca (israel) ltd - quetiapine fumarate - טבליות עם שחרור נרחב - quetiapine fumarate 300 mg - quetiapine
סרוקואל 50 מג xr
astrazeneca (israel) ltd - quetiapine fumarate - טבליות עם שחרור נרחב - quetiapine fumarate 50 mg - quetiapine
סרוקואל 400 מג xr
astrazeneca (israel) ltd - quetiapine fumarate - טבליות עם שחרור נרחב - quetiapine fumarate 400 mg - quetiapine
נקסיום טבליות 20 מג
astrazeneca (israel) ltd - esomeprazole - טבליה - esomeprazole 20 mg - esomeprazole - esomeprazole - nexium tablets are indicated for: gastroesophageal reflux disease (gerd): - treatment of erosive reflux esophagitis - long-term management of patients with healed esophagitis to prevent relapse - symptomatic treatment of gastroesophageal reflux disease (gerd). in combination with an appropriate antibacterial therapeutic regimen for the eradication of helicobacter pylori and: - healing of helicobacter pylori associated duodenal ulcer and - prevention of relapse of peptic ulcers in patients with helicobacter pylory associated ulcers. - healing of gastric ulcers associated with nsaid therapy. - prevention of gastric and duodenal ulcers associated with nsaid therapy in patients at risk.prolonged treatment after i.v induced prevention of rebleeding of peptic ulcers.
נקסיום טבליות 40 מג
astrazeneca (israel) ltd - esomeprazole - טבליה - esomeprazole 40 mg - esomeprazole - esomeprazole - nexium tablets are indicated for: gastroesophageal reflux disease (gerd): - treatment of erosive reflux esophagitis - long-term management of patients with healed esophagitis to prevent relapse - symptomatic treatment of gastroesophageal reflux disease (gerd). in combination with an appropriate antibacterial therapeutic regimen for the eradication of helicobacter pylori and: - healing of helicobacter pylori associated duodenal ulcer and - prevention of relapse of peptic ulcers in patients with helicobacter pylory associated ulcers. - healing of gastric ulcers associated with nsaid therapy. - prevention of gastric and duodenal ulcers associated with nsaid therapy in patients at risk.prolonged treatment after i.v induced prevention of rebleeding of peptic ulcers.
לינפארזה 100 מג
astrazeneca (israel) ltd - olaparib - טבליות מצופות פילם - olaparib 100 mg - olaparib
לינפארזה 100 מג
astrazeneca (israel) ltd - olaparib - טבליות מצופות פילם - olaparib 100 mg - olaparib
לינפארזה 150 מג
astrazeneca (israel) ltd - olaparib - טבליות מצופות פילם - olaparib 150 mg - olaparib
לינפארזה 150 מג
astrazeneca (israel) ltd - olaparib - טבליות מצופות פילם - olaparib 150 mg - olaparib